Medicine recalls
|
| |
| Singapore: Recall of Naropin Injection 1% |
| |
Health Sciences Authority (HSA) announces that DCH Auriga Singapore is recalling one batch of Naropin Injection 1% (ropivacaine) (batch number: L6018A) to the retail level because visible punctures are present in some of the blister packaging of the ampoules. The integrity of the ampoules is not affected.
The product is indicated for surgical anaesthesia and analgesia.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/announcements/product-recall/recall-of-naropin-injection-1
In Hong Kong, Naropin Inj 10mg/ml (HK-42883) is a pharmaceutical product registered by Aspen Pharmacare Asia Limited O/B Aspen Pharmacare Asia Limited (Aspen). The product is a prescription-only medicine. As confirmed by Aspen, the manufacturer of the product in the above HSA announcement is different from the Hong Kong registered products and the affected batch has not been imported into Hong Kong.
Ends/Friday, Jan 30, 2026
Issued at HKT 17:30
|
| |
